PT  - JOURNAL ARTICLE
AU  - Sade, Maayan Yitshak
AU  - Shi, Liuhua
AU  - Colicino, Elena
AU  - Amini, Heresh
AU  - Schwartz, Joel D
AU  - Di, Qian
AU  - Wright, Robert O
TI  - Long-term air pollution exposure and diabetes risk in American older adults: a national cohort study
AID  - 10.1101/2021.09.09.21263282
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2021.09.09.21263282
4099  - http://medrxiv.org/content/early/2022/03/30/2021.09.09.21263282.short
4100  - http://medrxiv.org/content/early/2022/03/30/2021.09.09.21263282.full
AB  - Background Type 2 diabetes is a major public health concern. Studies show that both genetics and environmental exposures play a significant role in developing the disease. We assessed the association between air pollution and first documented diabetes occurrence in a national U.S. cohort of older adults to estimate diabetes risk.Methods We included all Medicare enrollees 65 years and older in the fee-for-service program, part A and part B, in the contiguous United States (2000-2016). Participants were followed annually until the first recorded diabetes diagnosis, end of enrollment, or death (264,869,458 person-years). We obtained annual estimates of fine particulate matter (PM2.5), nitrogen dioxide (NO2), and warm-months ozone (O3) exposures from highly spatiotemporally resolved prediction models. We assessed the simultaneous effects of the pollutants on diabetes risk using survival analyses. We repeated the models in cohorts restricted to ZIP codes with air pollution levels not exceeding the national ambient air quality standards (NAAQS) during the study period.Results We identified 10,024,879 diabetes cases of 41,780,637 people (3.8% of person-years). The hazard ratio (HR) for first diabetes occurrence was 1.074 (95% CI 1.058; 1.089) for 5 µg/m3 increase in PM2.5, 1.055 (95% CI 1.050; 1.060) for 5 ppb increase in NO2, and 0.999 (95% CI 0.993; 1.004) for 5 ppb increase in O3. Both for NO2 and PM2.5 there was evidence of non-linear exposure-response curves with stronger associations at lower levels (NO2 ≤ 40 ppb, PM2.5 ≤ 9 µg/m3). Furthermore, associations remained in the restricted low-level cohorts. The O3-diabetes exposure-response relationship differed greatly between models and require further investigation.Conclusion Exposures to PM2.5 and NO2 are associated with increased diabetes risk, even when restricting the exposure to levels below the NAAQS set by the U.S. EPA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the HERCULES Center (P30 ES019776), the Mount Sinai transdisciplinary center on early environmental exposures (P30 ES023515), the National Institute on Aging (NIA/NIH R01 AG074357), the National Institute of Environmental Health Sciences (R21 ES032606, R01 ES032242, 5U2CES026555-03, and R01 ES013744, P30 ES000002, R01 ES032418), and the United States Environmental Protection Agency (US EPA) (RD-83587201). Its contents are solely the responsibility of the grantee and do not necessarily represent the official views of the US EPA. Furthermore, the US EPA does not endorse the purchase of any commercial products or services mentioned in the publication. Finally, H.A. is supported by Novo Nordisk Foundation Challenge Programme: Harnessing the Power of Big Data to Address the Societal Challenge of Aging (NNF17OC0027812).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Mount Sinai institutional review board (Study 20-01344)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe Medicare data includes protected health information and therefore cannot be shared. Researchers who wish to use the data may contact the center for Medicare and Medicaid services directly.